Physician profile
Mickey L Smith
NPI 1821434713
$5,087.95
in general payments reported to CMS, 2019-2025
37 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.67 · 2020: $1,253 · 2021: $985 · 2022: $662 · 2023: $649 · 2024: $667 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $817.74 | 2020-2024 | Target |
| Abbvie INC. | $714.51 | 2022-2025 | Botox |
| Penumbra, INC. | $493.67 | 2020-2024 | Penumbra System, Red 72, Artemis |
| Depuy Synthes Sales INC. | $397.38 | 2020-2025 | Cerebase, Trufill |
| Medtronic USA, INC. | $355.61 | 2020 | |
| Providence Medical Technology, INC. | $324.73 | 2020-2022 | |
| Nuvasive, INC. | $258.89 | 2022 | |
| Microvention, INC. | $224.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $199.61 | 2021-2024 | Andexxa |
| Medtronic, INC. | $170.98 | 2025 | Strata |
| Globus Medical, INC. | $147.35 | 2025 | Excelsius Gps |
| Arbor Pharmaceuticals, INC. | $97.62 | 2020-2022 | |
| Irras USA, INC. | $85.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $72.27 | 2024-2025 | |
| Livanova USA, INC. | $62.90 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $61.46 | 2023 | |
| Innovation Technologies INC | $55.98 | 2021 | |
| Nico Corporation | $55.06 | 2024 | |
| Integra Lifesciences Corporation | $45.62 | 2021-2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Nevro Corp. | $44.05 | 2021-2024 | Senza |
| Smith+Nephew, INC. | $43.28 | 2023 | Bone Anchors With Arthroscopic Delivery System |
| Ucb, INC. | $42.62 | 2024 | Nayzilam |
| Genentech USA, INC. | $37.31 | 2021-2022 | |
| Boston Scientific Corporation | $32.19 | 2025 | General - Pain Management |
| Averitas Pharma INC. | $28.66 | 2023 | Qutenza |
| Si-Bone, INC. | $25.52 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $21.81 | 2022 | |
| Biotronik Nro, INC. | $19.86 | 2025 | |
| Curonix LLC | $18.82 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Eisai INC. | $17.90 | 2022 | |
| Misonix INC | $17.85 | 2020 | |
| Abbott Laboratories | $17.84 | 2025 | Perclose Prostyle |
| Csl Behring | $16.67 | 2019 | |
| Emd Serono, INC. | $16.49 | 2024 | |
| Lilly USA, LLC | $16.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.52 | 2022 | |
| Cerapedics INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mickey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.